Clinical Edge Journal Scan

Breast cancer survivors face increased risk for sexual dysfunction


 

Key clinical point: Female breast cancer (BC) survivors are at a higher risk of experiencing sexual dysfunction symptoms compared with women from the general population.

Major finding: The risk for sexual dysfunction was higher in female BC survivors compared with women from the general population (hazard ratio [HR] 1.60; 95% CI 1.51-1.70), with the risk being more prominent within the first 5 years after BC diagnosis (HR 2.05; 95% CI 1.89-2.22) and in women who were <50 years old at the time of BC diagnosis (HR 3.05; 95% CI 2.65-3.51).

Study details: Findings are from the Utah Population Database cohort study including 19,709 women age ≥18 years who had survived BC and 93,389 age- and birth state-matched women from the general population.

Disclosures: This study was supported by grants from the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Chang CP et al. Breast cancer survivorship and sexual dysfunction: A population-based cohort study. Breast Cancer Res Treat. 2023 (May 9). Doi: 10.1007/s10549-023-06953-9

Recommended Reading

Atezolizumab is associated with enhanced response in triple-negative breast cancer
MDedge Hematology and Oncology
Genomic assay changes minds on HER2+ BC treatment
MDedge Hematology and Oncology
HR+ early BC patients could briefly interrupt endocrine therapy to attempt pregnancy
MDedge Hematology and Oncology
Anthracycline+taxane combo reduces BC recurrence more effectively than either drug alone
MDedge Hematology and Oncology
Better lifestyle index scores associated with improved mortality and disease recurrence in high-risk BC
MDedge Hematology and Oncology
Postmastectomy implants did not increase risk for squamous cell carcinoma in BC patients
MDedge Hematology and Oncology
HER2+ early BC: Extent of disease at diagnosis may predict risk for relapse even after pCR
MDedge Hematology and Oncology
125I seed placement before neoadjuvant chemotherapy good marking method for metastatic lymph nodes in BC
MDedge Hematology and Oncology
Anlotinib-chemotherapy combo shows good efficacy and safety in metastatic TNBC
MDedge Hematology and Oncology
Are family members of early-onset BC patients at risk for discordant early-onset cancers?
MDedge Hematology and Oncology